Tandem Diabetes Care Inc (TNDM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tandem Diabetes Care Inc (TNDM) has a cash flow conversion efficiency ratio of 0.083x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($11.05 Million) by net assets ($132.40 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TNDM net asset quality index to measure how much of total assets are equity-financed.
Tandem Diabetes Care Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Tandem Diabetes Care Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Tandem Diabetes Care Inc to evaluate the quality of earnings relative to operating cash generation.
Tandem Diabetes Care Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tandem Diabetes Care Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SK ETERNIX CO LT
KO:475150
|
0.497x |
|
LAMDA Development S.A.
AT:LAMDA
|
-0.046x |
|
Amata Corporation Public Company Limited
BK:AMATA
|
0.105x |
|
TotalEnergies EP Gabon S.A.
PA:EC
|
0.068x |
|
Fujian Boss Software Development Co Ltd
SHE:300525
|
0.016x |
|
Jsti Group
SHE:300284
|
-0.038x |
|
CATARC Automotive Proving Ground Co.Ltd.
SHE:301215
|
N/A |
|
MYT Netherlands Parent BV
NYSE:MYTE
|
0.045x |
Annual Cash Flow Conversion Efficiency for Tandem Diabetes Care Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Tandem Diabetes Care Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Tandem Diabetes Care Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $155.17 Million | $-9.72 Million | -0.063x | -168.04% |
| 2024-12-31 | $263.10 Million | $24.23 Million | 0.092x | +190.78% |
| 2023-12-31 | $313.63 Million | $-31.81 Million | -0.101x | -188.42% |
| 2022-12-31 | $439.95 Million | $50.46 Million | 0.115x | -55.39% |
| 2021-12-31 | $433.11 Million | $111.36 Million | 0.257x | +281.78% |
| 2020-12-31 | $366.31 Million | $24.67 Million | 0.067x | -68.67% |
| 2019-12-31 | $194.98 Million | $41.91 Million | 0.215x | +439.16% |
| 2018-12-31 | $131.28 Million | $-8.32 Million | -0.063x | -102.79% |
| 2017-12-31 | $-29.15 Million | $-66.14 Million | 2.269x | -78.02% |
| 2016-12-31 | $-5.93 Million | $-61.17 Million | 10.321x | +1214.73% |
| 2015-12-31 | $63.47 Million | $-58.76 Million | -0.926x | +17.68% |
| 2014-12-31 | $54.57 Million | $-61.38 Million | -1.125x | -172.10% |
| 2013-12-31 | $115.54 Million | $-47.76 Million | -0.413x | -230.97% |
| 2012-12-31 | $-106.05 Million | $-33.47 Million | 0.316x | +4.43% |
| 2011-12-31 | $-71.29 Million | $-21.55 Million | 0.302x | -- |
About Tandem Diabetes Care Inc
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and … Read more